4.19 - 4.53
3.17 - 26.41
Join Discuss about ALVR with like-minded investors
in ALVR around 10 it didn't break VWAP, I am sure someone got squeezed there (the stock had 12% short float to start with)
62 Replies 8 👍 6 🔥
Question maybe for @maletone, but anyone really. I get the $CRXT parabolic trade, seeing it ramp up w/ volume and blow a top. But I don't get $ALVR this morning. Tips on how to look at the day one gapper and judge risk? It ramps from the open with high volume, but seems harder to tell when it's going to let up...
149 Replies 10 👍 15 🔥
Next Dividend Date
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.